Abstract: The present invention relates to the use of ajoene for inhibiting integrin-mediated cell-cell fusion. Specific types of cell-cell fusion are giant multinucleated cell formation, syneytia formation, and osteoclast formation.
Type:
Grant
Filed:
January 11, 1996
Date of Patent:
November 9, 1999
Assignee:
John B. Davidson
Inventors:
Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson
Abstract: The progression of infection and other pathologies produced by a viral infection may be inhibited by administering an effective dosage of Ajoene. Additionally, Ajoene has anti-tumor, anti-shock, and antiinflammation effects. In general, Ajoene may be used to treat any integrin-mediated disease or condition.
Type:
Grant
Filed:
January 11, 1996
Date of Patent:
September 7, 1999
Assignee:
John B. Davidson
Inventors:
Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson
Abstract: The progression of infection and other pathologies produced by a viral infection may be inhibited by administering an effective dosage of Ajoene. Additionally, Ajoene has anti-tumor, anti-shock, and anti-inflammation effects. In general, Ajoene may be used to treat any integrin-mediated disease or condition.
Type:
Grant
Filed:
January 11, 1996
Date of Patent:
January 26, 1999
Assignee:
John B. Davidson
Inventors:
Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson
Abstract: The progression of infection and other pathologies produced by a viral infection may be inhibited by administering an effective dosage of Ajoene. Additionally, Ajoene has anti-tumor, anti-shock, and anti-inflammation effects. In general, Ajoene may be used to treat any integrin-mediated disease or condition.
Type:
Grant
Filed:
January 11, 1996
Date of Patent:
January 5, 1999
Assignee:
John B. Davidson
Inventors:
Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson